Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

Delayed Quote. Delayed  - 09/27 10:00:00 pm
314.53 USD   +1.52%
09/23 BIOGEN : Citadel Advisors buys $426,432,864 stake in Biogen Inc (BII..
09/16 BIOGEN : AbbVie -New Data Presented At ECTRIMS Reinforce Efficacy of..
09/14 BIOGEN : to Report Third Quarter 2016 Financial Results on October 2..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
09/23 BIOGEN : Citadel Advisors buys $426,432,864 stake in Biogen Inc (BIIB)
09/16 BIOGEN : AbbVie -New Data Presented At ECTRIMS Reinforce Efficacy of ZINBRYTA (d..
09/14 BIOGEN : to Report Third Quarter 2016 Financial Results on October 26, 2016
09/14 BIOGEN : New Data Affirm Strong Efficacy and Well-Characterized Safety Profile o..
09/09 BIOGEN INC (NASDAQ : BIIB) To Present New MS Data At 32nd ECTRIMS Congress
09/08 BIOGEN : Demonstrates Commitment to Improving Patient Outcomes with Study on Bur..
09/07 EXCLUSIVE - GW PHARMACEUTICALS HIRES : sources
09/02 Anadarko, Colgate-Palmolive and Biogen rise; VeriFone dives
09/02 BIOGEN INC (NASDAQ : BIIB) Lands FDA Fast-Track Status For Alzheimer’s Can..
09/01DJBiogen's Alzheimer's Therapy Granted FDA Fast-Track Status
More news
Sector news : Specialty & Advanced Pharmaceuticals
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
09/27 Shire returns rights to Humira biosimilar to Momenta Pharma
09/26 Biogen completes NDA submission for nusinersen for spinal muscular atrophy, r..
09/20 Bayer Without Monsanto
09/19 Novartis' Multiple Sclerosis Life Cycle Looks More Assured
09/19 NASTY WEEKEND : Time To Think Through Trump-Era Investing
Advertisement
Financials ($)
Sales 2016 11 473 M
EBIT 2016 5 915 M
Net income 2016 4 015 M
Finance 2016 1 436 M
Yield 2016 -
P/E ratio 2016 17,22
P/E ratio 2017 15,94
EV / Sales 2016 5,88x
EV / Sales 2017 5,75x
Capitalization 68 920 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 345 $
Spread / Average Target 9,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George A. Scangos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
Adriana Karaboutis Executive VP-Technology & Business Solutions
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC2.67%67 888
ABBVIE INC9.00%104 341
MERCK KGAA6.80%13 828
KYOWA HAKKO KIRIN CO L..-14.86%9 116
MALLINCKRODT PLC-4.56%7 658
JAZZ PHARMACEUTICALS P..-10.44%7 493
More Results